The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Winrevair (sotatercept)

On 28 June 2024 the European Medicines Agency has issued a press release to say that the CHMP (human medicines committee) has recommended granting a marketing authorisation in the European Union (EU) for Winrevair (sotatercept) to treat adult patients with pulmonary arterial hypertension (PAH), in combination with other specific PAH therapies, to improve exercise capacity. This is the first step towards the release of the marketing authorisation for sotatercept which should now be imminent, A very exciting moment for the entire pulmonary hypertension community!

Read full press release at this link on the European medicine’s Agency website.

TRANSLATE »
Scroll to Top